Sysmex (OTCMKTS:SSMXY) Issues FY 2026 Earnings Guidance

Sysmex (OTCMKTS:SSMXY) updated its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 0.382-0.382 for the period, compared to the consensus EPS estimate of 0.440. The company issued revenue guidance of $3.4 billion-$3.4 billion, compared to the consensus revenue estimate of $3.1 billion.

Analyst Ratings Changes

Separately, Zacks Research cut Sysmex from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Sysmex currently has a consensus rating of “Hold”.

Sysmex Stock Up 6.2%

Shares of Sysmex stock traded up $0.64 on Friday, reaching $10.94. The stock had a trading volume of 31,539 shares, compared to its average volume of 214,687. The company has a quick ratio of 2.46, a current ratio of 3.26 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $6.89 billion, a P/E ratio of 28.79 and a beta of 1.05. The company has a 50 day moving average price of $9.34 and a 200 day moving average price of $9.06. Sysmex has a 1 year low of $8.01 and a 1 year high of $14.20.

Sysmex (OTCMKTS:SSMXY) last posted its earnings results on Friday, August 7th. The company reported $0.09 EPS for the quarter, beating analysts’ consensus estimates of $0.07 by $0.02. Sysmex had a net margin of 7.13% and a return on equity of 7.23%. Sysmex has set its FY 2026 guidance at 0.382-0.382 EPS. As a group, equities research analysts forecast that Sysmex will post 0.42 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.